AMRN: Amarin Corporation plc PEG Multiple
Amarin Corporation plc (AMRN) revenues are based on the sale of the drug Vascepa, which is reflected in the peg_co multiple, where 0.00 expresses the metric's current value. Business efficiency is supported by a streamlined distribution of cardiology products to pharmacy chains. Sales stability is further ensured by the diversified delivery of purified fish oil across international routes that comply with stringent quality standards.
Amarin (AMRN) - metric breakdowns and financial figures
The PEG ratio dynamics reflect the ability of Amarin Corporation plc (AMRN) to withstand generic expansion and monetize Vascepa in new markets. This metric relates the market value of earnings to their growth rate, allowing for the identification of an undervalued asset when the value is below one, which is critical for protecting capital from stagnation in the mature pharmaceutical sector.
